lg1

Doxenitoin is an anticonvulsant agent.

LG100754 (UVI 2112) is an insulin sensitizer that functions through RXR. LG100754 is an RXR dimer modulator. LG100754 acts as an RXR: RXR homodimer antagonist, but functions as an agonist towards RXR: PPARα and RXR: PPARγ heterodimers.

LG100268 is a potent, selective, and orally active retinoid X receptor (RXR) agonist that agonizes RXR-α, RXR-β, and RXR-γ at the nanomolar level, selectively exceeding the RAR by three orders of magnitude.LG100268 is capable of inducing transcriptional activation in adipocytes; affecting the RXRs and their chaperone receptor, Foxl2/Dmrt1, to induce flounder masculinization in juvenile flounder; inhibits keratin 17 expression in nigrostriatal epithelial cells; and increases PD-L1 expression in HER2 or triple-negative breast cancer.

LG190119 is a nonsecosteroidal vitamin D receptor modulator. It effectively inhibited LNCaP xenograft tumor growth without increased serum calcium levels or any other apparent side effects. It also inhibits the growth of LNCaP xenograft tumors in athymic

LG190178, a vitamin D receptor (VDR) ligand, is a therapeutic agent used for the treatment of psoriasis, osteoporosis, and secondary hyperparathyroidism.

LG190155 is a moderately potent VDR agonist. Vitamin D receptor (VDR) agonists are well known for their capacity to control calcium and bone metabolism and to regulate growth and differentiation of many cell types.

LG157 is a strong inhibitor of the mitotic kinesin-like protein 2 (MKLP2) [1].

Anti-B7-H6/NCR3LG1 Antibody is a human-derived antibody expressed in CHO cells, targeting B7-H6/NCR3LG1. It features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa.

Medifoxamine (LG 152) is a selective non-monoamine oxidase inhibitor that exhibits antidepressant activity through inhibition of 5 HT reuptake.Medifoxamine preferentially inhibits dopamine reuptake.

LG-121071 is an orally active selective androgen receptor modulator (SARM) with a Ki of approximately 17 nM for the androgen receptor. It is commonly used in studies of androgen receptor-related diseases, such as prostate cancer.

IDO-IN-5 is an indoleamine 2,3-dioxygenase (IDO) inhibitor (IC50: 1-10 μM).

IDO-IN-6 is an indoleamine 2,3-dioxygenase (IDO) inhibitor.

IDO-IN-8 is an indoleamine 2,3-dioxygenase (IDO) inhibitor (IC50: 1-10 μM).

LG-100064 is an agonist of retinoid-X-receptor (RXR)(EC50s of 330 nM, 200 nM, and 260 nM for RXRα, RXRβ and RXRγ)

RXR modulator

Sorbinicate is an antihypercholesterolaemic and vasodilating nicotinic acid ester.

LG-120907 is a nonsteroidal antiandrogen (NSAA) of the quinoline group with orally active. LG-120907 is a high-affinity antagonist of the androgen receptor (AR) with a Ki value of 26 nM.

PSB-1901 is a highly potent and selective A2B adenosine receptor antagonist exhibiting picomolar affinity for human A2BAR with exceptional subtype selectivity exceeding 10,000-fold over other adenosine receptors, while maintaining comparable potency in mouse A2BAR, making PSB-1901 a powerful pharmacological probe for preclinical investigations of adenosine-mediated signaling pathways.

PLG-101 is an antibody targeting CD8 and can be used for immunology research.